RESEARCH ARTICLE

NORTH AMERICAN ACADEMIC RESEARCH (NAAR) JOURNAL
2021 MARCH, VOLUME 4, ISSUE 3, PAGES 281-292
https://doi.org/10.5281/zenodo.4662018

Real-World Study of The Factors Affecting the Anticoagulant Therapy and Prognosis in Atrial Fibrillation Patients

Sharma Ram Kripal[1], Dr. Gaofeng Zeng[1*], Jianfeng Wu[1], Hongfa Yang[1], Kong Chen[1],

[1]Department of Cardiovascular Medicine, Key Laboratory of Heart Failure Prevention & Treatment of Hengyang, Clinical Medicine Research Center of Arteriosclerotic Disease of Hunan Province, The Second Affiliated Hospital of University of South China, Hengyang, 421001, Hunan Province, China.

OPEN ACCESS

Accepted Mar 31,2021
Published Apr 04,2021

***Corresponding Author:**
Dr.Gao-Feng Zeng
Chief Physician, Professor
2379795177@qq.com

DOI :https://doi.org/10.5281/zenodo.4662018

Pages: 281-292

Funding: University of South China

How to cite this article (APA):
Kripal, S, M., Zeng, G., Wu, J., Yang, H., & Chen, K. (2021). Real-World Study of The Factors Affecting the Anticoagulant Therapy and Prognosis in Atrial Fibrillation Patients. *North American Academic Research, 4(3)*,281-292.doi: https://doi.org/10.5281/zenodo.4662018

Conflicts of Interest
There are no conflicts to declare.

ABSTRACT

This paper examines the present context of the study of the factors affecting anticoagulant therapy and prognosis in Atrial Fibrillation patients. It is notable that "Atrial fibrillation" is one of the leading causes of mortality and morbidity. It is also the high-risk point factor of stroke in humans. The therapy "Anticoagulation can effect effectively on the stroke. Moreover, it is referred to as atrial fibrillation. Howbeit, the world of pharmacy referred to the standard anticoagulation of patients with atrial fibrillation is not very popular. Investigate the status of anticoagulation and its influencing factors to find the factors that affect anticoagulation therapy and provide a basis for guiding clinical decisions.

Keywords: PATIENTS WITH ATRIAL FIBRILLATION, NON-ANTICOAGULATION GROUP, ANTICOAGULATION GROUP, WARFARIN ANTICOAGULATION GROUP.

Introduction

"Atrial fibrillation (AF)" is the typical standard "cardiovascular arrhythmia," by the various noteworthy predominance in older sufferers, and is portrayed by an unpredictable heart rhythm that may bring about clots in the heart that can spread all through the circulatory framework. There is a motivational progression in the healthcare sectors of developing nations. Its recurrence is anticipated to dramatically increase by mid-century, mirroring the developing extent of older people.[1] The "AF influences the quality of life significantly and is connected with the permanent inability, unsettling intellectual influence, hospitalization, nonappearance from work, just as a fivefold expanded frequency of stroke." There approximately one fourth of cases recorded in this segment. The points of AF the executives are, subsequently, "two-crease: rate/rhythm

control and anticoagulation. In patients with AF, anti-inflammatory (aspirin) medicine decreases stroke by 22 % contrasted and placebo." Notwithstanding, sufferers treated with anti-inflammatory (aspirin) medicine have an expanded bleeding danger like that of "Vitamin K, the enemy (VKA)- treated patients. VKAs have supplanted the utilization of aspirin medicine for stroke avoidance, and aspirin medicine is not suggested for this sign. "The adequacy of oral anticoagulant (OAC) treatment for stroke anticipation in AF (SPAF) has been entrenched; anticoagulation utilizing VKAs, for example, warfarin has been the backbone of AF treatment for a long time."

In any case, in the most recent decade, the restrictions of VKAs have prompted the improvement of "non-VKA oral anticoagulants (NOACs), including Dabigatran (a direct thrombin inhibitor), apixaban, rivaroxaban and edoxaban (factor Xa inhibitors)." In clinical preliminaries, all "NOACs" have demonstrated non-inadequacy and some prevalence over warfarin as far as stroke avoidance and bleeding danger. In any case, the advantage chance proportion of OAC treatment, i.e., the net advantage of hazard decreases of "embolic ischemic occasions" versus the expanded hazard for dying, ought to be evaluated depending upon the situation. It empowers treatment to be custom fitted to the particular necessities and hazard variables of a person. This review will talk about individualizing anticoagulant treatment in AF patients.

The "Non-Vitamin K adversary (VKA) oral anticoagulants (NOACs)" have risen as options to VKAs for the anticipation of stroke in people with "non-valvular atrial fibrillation." Four NOACs: "Dabigatran, Apixaban, Rivaroxaban, and Edoxaban," have gotten administrative endorsement in "Europe from the European Medicines Agency." In any case, NOACs offer the open door for individualized treatment dependent on variables, for example, "renal capacity, age, or patient/specialist inclination" for more than once every day dosing regimens. Portion decrease of some NOACs ought to be considered in danger understanding populaces. [2,3,4]

Materials and methods

- **AGE**

Around "15 % of patients with AF are <60 years old, while more than 33% of patients with "AF are ≥75 years" of age." All anticoagulants will cause more bleedings in older patients, particularly within sight of other bleeding danger factors. In the "RE-LY preliminary, most extreme number of patients were ≥75 years old. "With expanding age, the advantage in diminishing significant bleedings was weakened with comparative and higher bleeding rates contrasted and warfarin for Dabigatran 110 mg twice day by day and 150 mg twice day by day, separately in a pre-indicated auxiliary investigation of the "ARISTOTLE preliminary; patients were delineated into age classes: <65 (n=5,471), 65–74 (n=7,052) and ≥75 (n=5,678) years.[5]" The advantages of apixaban in stroke avoidance demonstrated no communication with age. "Apixaban diminished the pace of significant bleeding contrasted and warfarin with a predictable treatment impact across age ranges." In a pre-indicated auxiliary examination of the "ROCKET-AF, patients were defined into age classifications: <75

(n=8,021) and ≥75 (n=6,215) years." The danger of significant bleeding and the danger of stroke/SEE expanded with age. The viability of "Rivaroxaban" in stroke counteraction and the event of bleeding indicated a strong treatment impact across age gatherings. In a pre-indicated auxiliary investigation of the "Draw in AF-TIMI 48 preliminary, patients were defined into age classifications: <65 (n=5,497), 65–74 (n=7,134) and ≥75 (n=8,474) years." In outline, in stage III preliminaries, when contrasted with warfarin, as far as viability and security, the advantages of NOAC treatment are reliable, paying little heed to age.[6]

- **"Renal Function"**

"Chronic kidney disease (CKD)" is reasonable in patients (evaluated "glomerular filtration rate [eGFR] 30–60 mL/min).[7] "Among NOACs, renal liberation differs significantly, from "27 % for apixaban to 85 % for Dabigatran." [8] In this way, renal function ought to be checked yearly, yet more much of the time in "patients ≥75 years old utilizing Dabigatran or edoxaban," for example at a half-year interval. Quarterly observing of the problem is suggested in sufferer's with "CrCl 15–30 ml/min."[9]

1. Objectives

The purposes of these systematic reviews are:

(a) To analyze the patients with Atrial Fibrillation in a real-world context.

(b) To analyze factors affecting Anticoagulant therapy in Atrial Fibrillation patients.

(c) To analyze and their impact on in the new oral anticoagulant group and non- standard medication group.

2. Evaluation of Stroke Risk

There are several reviews are presently identified as the most compatible independent risk determinants for AF-related stroke. Howbeit, the risk layer designs based on reasonable ominous significance for recognizing high- fatal patients. Consequently, the focus has moved towards distinguishing low-risk patients that do not require anticoagulation treatment.[10] There are some international guidelines, "the CHA2DS2-Vasc risk score (congestive heart failure (such as- left ventricular ejection fraction (LVEF) <40 %), hypertension, diabetes, vascular disease such as prior myocardial infarction (MI), peripheral arterial disease (PAD)], age 65–75, female sex all 1 point; age ≥75, stroke/transient ischemic attack (TIA) every 2 points) is used to identify low-risk patients."[11,12]

Table 1 "the pharmacokinetics characteristics of the Non- Vitamin K antagonist oral Anticoagulants and recommended Dosing"

Form of drug used	*"Dabigatran"*	*"Apixaban"*	*"Edoxaban"*
	This prodrug is used to converted to active	**It is not a prodrug**	**It is not a prodrug**

	Dabigatran		
Action mode followed	Thrombin inhibitor	FXa inhibitor	Same (Fxa inhibitor)
The presence of "Bioavailability"	Approx. 3- 7%	Approximately more than 50%	Approximately 62%
"Renal clearance"	86%	Approx. 27%	50 % approx..
Period(half-life's)	11-18 hr.	11-12 hrs.	11-13hrs
The level of plasma to trough level	2 hr.- 12hr	1-3 hrs. – 12 hrs.	1-2 hrs.- 13 hrs.
The metabolism of Liver (CYP3A4)	Not present	Adequate moderate	Ranges from 6-22 %
NOAC DOSE	150 mg/110mg two times a day	5 mg approx. two-time days	60 mg 1 time day
Dose Adaptation	Not in phase trial III a. SPC shows 110 mg two times a day, when CrCl half an hour -45 ml per min or bleeding risk high b. 72 mg two times a day if CrCl 30- 45 ml per min permitted and not verified	2.5 mg approximately two times day a. Creatinine greater and equal to 1.5 mg per dL b. Age greater than equal to 80 year c. Less than 60 kg	30 mg one day if: a. CrCl half an hour to 50 ML/ min b. <60 kg c. Use of inhibition (cyclosporin, dronedarone. Ketoconazole and erythromycin)
NOAC not recommended (SPC)	CrCl < 30 ml per Min	CrCl < 15 ml per min	CrCL <15 ml per Min

The "CrCl- creatinine clearance, NOAC= non-vitamin K antagonist oral anticoagulant, P-gp= permeability glycoprotein, SPC = summary of product characteristics." Took from "Heidbuchel et al., 2015 [13]

Stroke hazard for AF patients with a CHA2DS2-Vasc score of 1 not on OAC treatment, fluctuates from 0.6 % to >2.0 %." "Utilizing a more extensive meaning of ischemic embolic occasions, including TIA and pneumonic embolism, the yearly occasion rate was 1.3 % in men. In a considerable review investigation of

“Danish Health libraries of AF patients, in untreated patients with a CHA2DS2-Vasc score of 0 (male) or 1 (female), the yearly stroke occasion rate was 0.49 %.” [14] In this survey, the yearly stroke chance expanded to 1.55 % in patients with one extra hazard factor. The higher age is the hazard factor related to the most elevated stroke chance. In an enormous Taiwanese populace-based investigation of AF patients with “CHA2DS2-Vasc score of 1 (male) or 2 (female) and not accepting anticoagulation treatment, ischemic stroke chance in men went from 1.96 %/year for men with a CHA2DS2-Vasc score or 1 dependent on the nearness of vascular illness to 3.50 %/year for men with a CHA2DS2-Vasc score of 1 dependent on an age of 65–74 years.” Given this information, in accordance with universal rules, oral anticoagulation ought to be considered in “AF patients” with additional problem related feature. [15,16,17]

3. Assessment of “Bleeding Risk”

"Bleeding" is the most dreaded complexity of OAC treatment. “Warfarin” related bleeding is liable for 33% of all hospitalizations for antagonistic medication events. [18] Many numbers of case of this can led to components for death. But the decrement in the stroke is enhanced in the circumstance of bleeding.

- “Three bleeding risk scores have been approved in AF populaces”: [19,20,21]

"The HEMORR$_2$HAGES, HAS-BLED, and ATRIA hazard scores." Howbeit, just "HAS-BLED" has been approved in substantial risk in populaces. Bleeding hazard evaluation utilizing the “HAS-BLED” chance score is hence suggested for all patients with AF. The "HAS-BLED" chance score allocates 1 point for every one of the accompanying: "hypertension (>160 mmHg); irregular renal/ liver capacity; past stroke; bleeding history or inclination, labile worldwide standardized proportion (INR), older, attendant medications/ liquor overabundance. HAS-BLED scores ≥3 prove a serious danger of bleeding."

The "HAS-BLED" score ought not to be utilized to prohibit patients from OAC treatment, though it shows the bleeding risks. In outline, the OAC treatment ought to be founded on the singular evaluation of stroke chance. As shown by the "European Society of Cardiology (ESC) rules," in AF patients with a CHA2DS2-VASc score of 0 in males or 1 in females (yearly stroke hazard <1 %/year), the commencement of OAC treatment is not suggested. In the AF suffers additional "CHA2DS2-Vasc" probability, OAC might be thought of. Notwithstanding, “CHA2DS2-Vasc score ≥2,” this can be look after the advantage point of view.[22]

4. Real world True Effectiveness Data of “Non-Vitamin K Antagonist Oral Anticoagulants”

The viability of “NOACs” has been built up inside the setting of well controlled stage III preliminaries, with exacting consideration and prohibition measures, control of treatment adherence and utilization of associative prescription. The security profile of NOACs exhibited in controlled preliminary settings might be diverse in a genuine setting. The relative viability of “Dabigatran versus warfarin” was concentrated in an enormous cohort of approximately 130,313 affinity score-coordinated Medicare recipients. Contrasted and “warfarin, Dabigatran diminished the danger of ischemic stroke (HR 0.80 [0.67–0.96]), intracranial drain (HR 0.34 [0.26–0.46]) and passing (HR 0.86 [0.77–0.96]); there were no distinctions between accomplices in danger of

significant dying (HR 0.97 (0.88–1.07) or intense MI (HR 0.92 [0.78–1.08]), and there was an expanded danger of gastro-intestinal dying (HR 1.28 [1.14–1.44]).” In the subgroup treated with “Dabigatran 110” mg twice day by day, none of the result examinations were factually altogether not quite the same as warfarin aside from a lower danger of dying. [23]

In an imminent, “non-interventional oral anticoagulation” vault of approximately day by day care patients. To date, no genuine world vault information is yet accessible for “Apixaban and edoxaban.” Information for “Edoxaban” are right now being accumulated through the “Edoxaban Treatment in Routine Clinical Practice – Atrial Fibrillation – Europe (ETNA-AF-Europe) vault.”

Howbeit, in spite of quick standardization of the INR, the anticipation of warfarin-related significant bleeding stays poor. For quick inversion of dangerous NOAC-related dying, the organization of PCC might be considered notwithstanding broad measures. [24]

As of late, information on explicit inversion operators has been known. “Idarucizumab,” a monoclonal immune response piece, was intended to explicitly opposite the anticoagulant impact of Dabigatran. The Inversion Effects of “Idarucizumab on Active Dabigatran” preliminary included patients with genuine bleeding or those requiring critical surgery. The preliminary, in any case, was not intended to look at clinical result information. Based on this information, in patients giving “Dabigatran-related life-threatening dying, Idarucizumab, a monoclonal neutralizer part,” is the favored inversion agent and has been demonstrated to be protected in starting clinical trials. “The accessibility of NOAC specific remedies may remove potential worries about inversion of NOAC action; howbeit these specialists ought to be saved forever undermining bleeding or for critical surgeries or thrombolysis. More observational information on genuine viability of NOACs will develop from on-going enormous vaults with every one of the four NOACs. [25,26]

5. “Non-vitamin K Antagonist Oral Anticoagulants: Pharmacokinetics” and Clinical Test Model

“Edoxaban and Rivaroxaban” are controlled once day by day, Dabigatran and apixaban twice every day (see Table 2). NOACs show minimal potential for sedate medication cooperations, and don't require portion modification based on coagulation tests like VKAs.[27]

Table 2

	ARISTOTLE	**RE-LY**
	5mg two TIMES DAILY (2.5 mg*)	“Dabigatran 110 or 150 mg 2 times daily
	Double blind	PROBE
	Comparator: warfarin, INR2.0-3.0	Comparator warfarin, INR 2-3

2 TIMES DAILY GREATER THAN EQUAL TOO RISK FACTOR	Reduction of dosage to 2.5 mg 2 times daily if 2: creatinine greater than equal to 1.5 mg per dl or greater than equal to 80 year or less than 60 kilograms	
1 TIME DAILY GREATET THAN EQUAL TOO 2 RISK FACTORS	**"ROCKET-AF"**	**{ENGAGE AF-TIMI48}**
	• Rivaroxaben 20 mg one day (approx. 15 milligram)	• Edoxaban approx. 30-60 milligram 1 time daily
	• Double- blind	• Double-blind
	• Comparator: Warfarin, INR 2-3	• Comparator: Warfarin, INR 2-3
	• *Dosage reduction to approx. 15 milligram 1 time day if approx. CrCl 30-49 ml per min	• * half dosage if CrCL approx. 30-50 ml or <60 kilogram or "P-gp inhibitors (Verapamil, quinidine)"

The "Intestinal absorption of NOACs" is dependent on permeability (glycoprotein (P-gp) transporter). Hence, co-medication is challenging "P-gp transporter will build NOAC plasma levels." These usually utilized in AF patients incorporate "verapamil, dronedarone, and quinidine." As Dabigatran has a much lower bioavailability than the different "NOACs (around 7 % versus ≥50 %), P-gp inhibitors will particularly influence Dabigatran levels." On the other hand, "P-gp inducers, for example, rifampicin, will decrease the NOAC plasma level."

"Cytochrome P450 (CYP3A4)" is associated with the hepatic freedom of rivaroxaban and, to a lesser degree, of apixaban and edoxaban, be that as it may, not of Dabigatran. Solid "CYP3A4 inducers or inhibitors" can impact their plasma levels, particularly rivaroxaban levels. In any case, patients with a high bleeding danger, a portion decrease of NOACs has been proposed when higher plasma levels can be normal.[28]

The "European Heart Rhythm Association (EHRA)" has distributed a down to earth manual for the utilization of NOACs. This gives proposals on: "starting treatment; observing the anticoagulant impact; drug-drug connections; exchanging between anticoagulant regimens; guaranteeing consistency; managing dosing mistakes; overseeing dying complexities, and extraordinary signs in patients experiencing careful intercessions or cardioversion; just as patients with an interminable kidney infection, intense stroke, coronary vein malady, and malignancies."[29]

6. The “Clinical Trials of PHASE III”

The adequacy and security of “NOACs for SPAF” have been set up in four critical stages III preliminaries. "Dabigatran, apixaban, rivaroxaban, and edoxaban" were concentrated in the "Randomized Evaluation of Long-term Anticoagulant Treatment (RE-LY) preliminary, the Apixaban for the Prevention of Stroke in Subjects with Atrial Fibrillation (ARISTOTLE) preliminary,” respectively. [30]

In the entirety of the stage III NOAC preliminaries in patients with AF, portion balanced warfarin with an objective INR of 2–3 was utilized as the comparator arm (Refer to above table 1 and 2). The essential endpoint in these preliminaries was the decrease in stroke and fundamental embolism, and the security endpoint was decreased in significant seeping as per the definition of the “International Society on Thrombosis and Hemostasis (ISTH).”

In the "RE-LY" preliminary, a planned randomized, (PROBE) configuration was utilized. Conversely, in the FXa inhibitor considers a double-blind, two-fold sham plan was utilized. A non-mediocrity configuration was utilized in all investigations, with continuous measurable testing for prevalence once the non-inadequacy edge was met. The decision for non-mediocrity plans depends on the demonstrated adequacy of warfarin in SPAF. The non-mediocrity limit, which is set to guarantee that the investigation tranquilizes jelly a pre-determined part of the advantage of warfarin over placebo, was set somewhere in the range of "<1.38 and <1.46," for example, the examination medication would be proclaimed non-second rate if the certainty interim prohibited that the essential result rate with the study "tranquilize>1.38 to >1.46" times higher than with warfarin. [31]

In the "RE-LY preliminary," two unique dosages of "Dabigatran, 110 mg or 150 mg 2 times day by day, were assessed, without portion reduction.” In the "ARISTOTLE preliminary, Apixaban 5 mg twice day by day was utilized, with portion decrease to 2.5 mg two times day by day for subjects who at benchmark satisfied two out of three models (age ≥80 years, body weight ≤60 kg and serum creatinine level ≥1.5 mg/dL [133 μmol/L])."

Patients with AF and ≥1 extra stroke hazard factor was remembered for the "RE-LY and the ARISTOTLE preliminaries, and with ≥2 extra stroke chance variables in the ROCKET-AF and the ENGAGE AF-TIMI 48 preliminary, for example, patients in the ROCKET-AF and the ENGAGE AF-TIMI 48 preliminary were at a greater danger of stroke contrasted and the patient populaces in the RE-LY and ARISTOTLE preliminaries.” [32]

Conclusion

In patients with “AF and ≥1 stroke hazard factor,” stage III preliminaries have exhibited the positive advantage hazard proportion in "SPAF of NOACs contrasted and VKA." Moreover, organized age and CKD increment the danger of seeping for both NOAC just as for VKA. “The benefits of NOACs are kept up in subgroups of older patients and patients with CKD. Due to higher paces of stroke and significant seeping in these subgroups, the supreme advantages of NOACs are significantly more prominent in these subgroups. In the nonappearance of no holds barred correlations, there is no single NOAC that can be suggested over the different NOACs.” Besides, the parental figure has the open door for customized care, given clinical factors. Attendant medicine may expand the danger of dying. Subsequently, following the “SPC of the individual NOACs, portion decrease of NOACs is to be considered within sight of medications that can be expected to expand the plasma level of NOACs.” Even though ibuprofen might be co-controlled with all NOACs, as a rule, to diminish the hazard of significant bleeding where conceivable, attending utilization of APT ought to be avoided. As the rate of coronary corridor illness and AF runs somewhere in the range of “24 and 46 %, 79 the board of patients treated with a NOAC and giving a coronary disorder may merit uncommon consideration.” At long last, quiet instruction and information move on SPAF are significant devices to expand consistency. Assets for patients are accessible online with the global cardiology social orders.

Acknowledgements

This work was supported by grants from the Special Funds for the Innovative Construction of Hunan Province (No. 2020SK4010), the Special Funds for Science and Technology Plan Project of Hengyang (No.2019jh426001), the Project of Health Commission of Hunan Province (No. B2019108, 20201533) and the Research Project of University of South China (No. nk2020106).

References

Zoni-Berisso M, Lercari F, Carazza T, Domenicucci S. Epidemiology of atrial fibrillation: European perspective. Clin Epidemiol 2014;6:213–20. DOI: 10.2147/CLEP.S47385; PMID: 24966695

Go AS, Hylek EM, Phillips KA, et al. Prevalence of diagnosed atrial fibrillation in adults: national implications for rhythm management and stroke prevention: the Anticoagulation and Risk Factors in Atrial Fibrillation (ATRIA) Study. JAMA 2001;285:2370–5. PMID: 11343485

Roger VL, Go AS, Lloyd-Jones DM, et al. Heart disease and stroke statistics–2012 update: a report from the American Heart Association. Circulation 2012;125:e2–220. DOI: 10.1161/CIR.0b013e31823ac046; PMID: 22179539

Wolf PA, Abbott RD, Kannel WB. Atrial fibrillation as an independent risk factor for stroke: the Framingham Study. Stroke 1991;22:983–8. PMID: 1866765

Halvorsen S, Atar D, Yang H, et al. Efficacy and safety of apixaban compared with warfarin according to age for stroke prevention in atrial fibrillation: observations from the ARISTOTLE trial. Eur Heart J 2014;35:1864–72. DOI: 10.1093/eurheartj/ehu046; PMID: 24561548; PMCID: PMC4104493

Sharma M, Cornelius VR, Patel JP, et al. Efficacy and Harms of Direct Oral Anticoagulants in the Elderly for Stroke

Prevention in Atrial Fibrillation and Secondary Prevention of Venous Thromboembolism: Systematic Review and Meta-Analysis. Circulation 2015;132:194–204. DOI: 10.1161/CIRCULATIONAHA.114.013267; PMID: 25995317

EMC, Eliquis 2.5 mg film-coated tablets. Summary of Product Characteristics. Available at: www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/002148/WC500107728.pdf (accessed 10 July 2015).

Kooiman J, van de Peppel WR, van der Meer FJ, Huisman MV. Incidence of chronic kidney disease in patients with atrial fibrillation and its relevance for prescribing new oral antithrombotic drugs. J Thromb Haemost 2011;9:1652–3. DOI: 10.1111/j.1538-7836.2011.04347.x; PMID: 21585647

Heidbuchel H, Verhamme P, Alings M, et al. Updated European Heart Rhythm Association Practical Guide on the use of non-vitamin K antagonist anticoagulants in patients with non-valvular atrial fibrillation. Europace 2015;17:1467–507. DOI: 10.1093/europace/euv309; PMID: 26324838

Lip GY, Lane DA. Stroke prevention in atrial fibrillation: a systematic review. JAMA 2015;313:1950–62. DOI: 10.1001/jama.2015.4369; PMID: 25988464

Lip GY. Stroke and bleeding risk assessment in atrial fibrillation: when, how, and why? Eur Heart J 2013;34:1041–9. DOI: 10.1093/eurheartj/ehs435; PMID: 23257951

Eckman MH, Singer DE, Rosand J, Greenberg SM. Moving the tipping point: the decision to anticoagulate patients with atrial fibrillation. Circ Cardiovasc Qual Outcomes 2011;4:14–21. DOI: 10.1161/CIRCOUTCOMES.110.958108; PMID: 21139092

Heidbuchel H, Verhamme P, Alings M, et al. Updated European Heart Rhythm Association Practical Guide on the use of non-vitamin K antagonist anticoagulants in patients with non-valvular atrial fibrillation. Europace 2015;17:1467–507. DOI: 10.1093/europace/euv309; PMID: 26324838

Friberg L, Skeppholm M, Terént A. Benefit of anticoagulation unlikely in patients with atrial fibrillation and a CHA2DS2-VASc score of 1. J Am Coll Cardiol 2015;65:225–32. DOI: 10.1016/j.jacc.2014.10.052; PMID: 25614418

Lip GY, Skjøth F, Rasmussen LH, Larsen TB. Oral anticoagulation, aspirin, or no therapy in patients with nonvalvular AF with 0 or 1 stroke risk factor based on the CHA2DS2-VASc score. J Am Coll Cardiol 2015;65:1385–94. DOI: 10.1016/j.jacc.2015.01.044; PMID: 25770314

Lip GY, Lane DA. Modern management of atrial fibrillation requires initial identification of "low-risk" patients using the CHA2DS2-VASc score, and not focusing on "high-risk" prediction. Circ J 2014;78:1843–5. PMID: 25008366

Chao TF, Liu CJ, Wang KL, et al. Should atrial fibrillation patients with 1 additional risk factor of the CHA2DS2-VASc score (beyond sex) receive oral anticoagulation? J Am Coll

Cardiol 2015;65:635–42. DOI: 10.1016/j.jacc.2014.11.046; PMID: 25677422; PMID: 25677422

Budnitz DS, Lovegrove MC, Shehab N, Richards CL. Emergency hospitalizations for adverse drug events in older Americans. N Engl J Med 2011;365:2002–12. DOI: 10.1056/NEJMsa1103053; PMID: 22111719

Pugh D, Pugh J, Mead GE. Attitudes of physicians regarding anticoagulation for atrial fibrillation: a systematic review. Age Ageing 2011;40:675–83. DOI: 10.1093/ageing/afr097; PMID: 21821732

Gage BF, Yan Y, Milligan PE, et al. Clinical classification schemes for predicting hemorrhage: results from the National Registry of Atrial Fibrillation (NRAF). Am Heart J 2006;151:713–9. PMID: 16504638

Pisters R, Lane DA, Nieuwlaat R, et al. A novel user-friendly score (HAS-BLED) to assess 1-year risk of major bleeding in patients with atrial fibrillation: the Euro Heart Survey. Chest 2010;138:1093–100. DOI: 10.1378/chest.10-0134; PMID: 20299623

Griffiths HR, Lip GY. New biomarkers and risk stratification in atrial fibrillation: simplicity and practicality matter. Circulation 2014;130:1837–9. DOI: 10.1161/CIRCULATIONAHA.114.012870; PMID: 25294785

Graham DJ, Reichman ME, Wernecke M, et al. Cardiovascular, bleeding, and mortality risks in elderly Medicare patients treated with dabigatran or warfarin for nonvalvular atrial fibrillation. Circulation 2015;131:157–64. DOI: 10.1161/CIRCULATIONAHA.114.012061; PMID: 25359164

Beyer-Westendorf J, Förster K, Pannach S, et al. Rates, management, and outcome of rivaroxaban bleeding in daily care: results from the Dresden NOAC registry. Blood 2014;124:955–62. DOI: 10.1182/blood-2014-03-563577; PMID: 24859362

Tamayo S, Frank Peacock W, Patel M, et al. Characterizing major bleeding in patients with nonvalvular atrial fibrillation: a pharmacovigilance study of 27 467 patients taking rivaroxaban. Clin Cardiol 2015;38:63–8. DOI: 10.1002/clc.22373; PMID: 25588595

German Clinical Trials Register. Non-interventional study on Edoxaban treatment in routine clinical practice for patients with non valvular atrial fibrillation - ETNA-AF-Europe DRKS00007912. Available at: http://drks-neu.uniklinik-freiburg.de/drks_web/navigate.do?navigationId=trial.HTML&TRIAL_ID=DRKS00007912 (accessed 20 October 2015).

Granger CB, Alexander JH, McMurray JJ, et al. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med 2011;365:981–92. DOI: 10.1056/NEJMoa1107039; PMID: 21870978

Patel MR, Mahaffey KW, Garg J, et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med 2011;365:883–91. DOI: 10.1056/NEJMoa1009638; PMID:

21830957

Giugliano RP, Ruff CT, Braunwald E, et al. Edoxaban versus warfarin in patients with atrial fibrillation. N Engl J Med 2013;369:2093–104. DOI: 10.1056/NEJMoa1310907; PMID: 24251359

Granger CB, Alexander JH, McMurray JJ, et al. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med 2011;365:981–92. DOI: 10.1056/NEJMoa1107039; PMID: 21870978

Ruff CT, Giugliano RP, Braunwald E, et al. Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials. Lancet 2014;383:955–62. DOI: 10.1016/S0140-6736(13)62343-0; PMID: 24315724

Camm AJ, Lip GY, De Caterina R, et al. 2012 focused update of the ESC Guidelines for the management of atrial fibrillation: an update of the 2010 ESC Guidelines for the management of atrial fibrillation. Developed with the special contribution of the European Heart Rhythm Association. Eur Heart J 2012;33:2719–47. DOI: 10.1093/eurheartj/ehs253; PMID: 22922413

Author: **Sharma Ram Kripal**
MBBS: Xuzhou Medical University, Xuzhou, Jiangsu, China.
PG: Resident Doctor (MD, Internal Medicine) at University of South China, Hengyang, Hunan, China.
Email: xzmc2010@yahoo.com